Clinical trial
Safety and Tolerability Study in Patients With Mild to Moderate Alzheimer's…
NCT00411580 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00411580 |
|---|---|
| Title | Safety and Tolerability Study in Patients With Mild to Moderate Alzheimer's Disease (AD) |
| Official title | A 52-week, Multi-center, Randomized, Double-blind, Placebo-controlled, Time-lagged, Parallel Group Study in Patients With Mild to Moderate Alzheimer's Disease (AD) to Investigate the Safety, Tolerability and Aß-specific Antibody Response Following Three Subcutaneous Injections of CAD106 |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Alzheimer's Disease |
| Intervention type | Biological, Drug |
| Interventions | CAD106, Placebo |
| Enrollment | 58 |
| Start date | Jun 1, 2005 |
| Primary completion | Dec 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | Dec 14, 2006 |
| Last update posted | Mar 29, 2013 |
| Countries | Sweden |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: